Paul Everson

LTbR emerging as an important TAM checkpoint

Levels of LTbR (Lymphotoxin beta Recpeptor) on TAM (Tumor Associated Macrophage) inversely correlate with anti-tumor response, indicating an immunosuppresive role. This Chinese research group demonstrate that disrupting this expression in mice by silencing or knockout causes tumor regression in a mouse lung carcinoma model. “LTBR acts as a novel immune checkpoint of tumor-associated macrophages for […]

LTbR emerging as an important TAM checkpoint Read More »

RAGE and CD147 are both receptors for cyclophilin A and are drivers of thrombo inflammation.

“Cyclophilin A is a ligand for RAGE in thrombo-inflammation” P Seizer, D Heinzmann, et al. Cardiovascular Research (2024) 120: 385-402. https://doi.org/10.1093/cvr/cvad189 PMID: 38175781 Ancell anti-CD147 antibody (clone UM-8D6) was used to block monocyte chemotaxis, induce NfkB translocation and to stimulate MyD88 antigen upregulation in monocytes. Ancell anti-CD147 mAb products

RAGE and CD147 are both receptors for cyclophilin A and are drivers of thrombo inflammation. Read More »

Induction of Suppressive NK-like cells

“Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization” DC Chung, PS Ohashi, et al. J Immunol(2024) 212(12): 1904-1912. https://doi.org/10.4049/jimmunol.2300834 PMID: 38668728 This Toronto based research group used a combination of TGF-b1 and IL-15 to induce a CD103+/CD49a+ phenotype in peripheral blood derived NK cells. Co incubation with this NK cell line inhibited CD4

Induction of Suppressive NK-like cells Read More »

Ancell anti-CD11b and CD18 mAbs used to block Trogocytotic killing

Ancell mAbs were used by this Cal State Research group to block trogocytic killing of Triconomas Vaginelas parasite by human PLB-95 Neutrophil-Like-cells in vitro. Blocking CD11c and CD18 receptors on NLC with antibodies resulted in significant reduction of killing, implicting CR3 mediated complement fixation as the primary mechanism. “Complement receptor 3 is required for maximum

Ancell anti-CD11b and CD18 mAbs used to block Trogocytotic killing Read More »

Ancell anti-CD11b and anti-CD54 Biotin reagents used to assess surface antigen expression and adhesion potential of Neutrophils

Russian Researchers investigating Redox processes in Neutrophil activation. “Redox processes are major regulators of leukotriene synthesis in neutrophils exposed to bacteria Salmonella typhimurium; the way to manipulate neutrophil swarming” E A Golenkina, G F Sud’ina, et al. (Feb 2024) Front. Immunol 15 (06 February 2024) PMID: 38384456 PMCID: PMC10880102 DOI: 10.3389/fimmu.2024.1295150 . Relevant Ancell Products

Ancell anti-CD11b and anti-CD54 Biotin reagents used to assess surface antigen expression and adhesion potential of Neutrophils Read More »

Ancell anti-CD18 F(ab’)2 used as a positve control to block Neutrophil adhesion to CD54 (b2-Integrin) on A431 cells

Researchers investigating the role of Siglec-5 in Neutrophil activation. “SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity” P Bouti, HL Matlung et al. (Dec 2023) Int J Mol Sci 24(24): 17141. https://doi.org/10.3390/ijms242417141 Relevant Ancell Products anti-human CD18 products anti-human CD11b products anti-human CD47 products Recombinant human CD54-muIg

Ancell anti-CD18 F(ab’)2 used as a positve control to block Neutrophil adhesion to CD54 (b2-Integrin) on A431 cells Read More »

Ancell anti-CTLA-4 mAb used to evaluate autoimmune ACS model

Acute Coronary Syndrome(ACS) was simulated by provoking healthy PBMC with autoimmune self antigen pepetide LL-37. Effect of blockade on HLA Class I, Class II, PD-1 and CTLA-4 on T cell expression of Activation Induced Molecules (AIM) was then examined. “Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome” Chernomordik F, PC Dermayuga, et al.

Ancell anti-CTLA-4 mAb used to evaluate autoimmune ACS model Read More »

A Review of Antibody Drug Conjugate (ADC) treatments for Lymphoma

“Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences” Marelia Barreca, et al. Explor Target Antitumor Ther. 2022; 3(6): 763–794. Published online 2022 Dec 26. doi: 10.37349/etat.2022.00112 PMID: 36654819 Relevant Ancell Research Products anti-human CD269(BCMA) mAb human CD269(BCMA) Recombinant Protein anti-human CD22 mAb anti-human CD79b anti-CD19 mAb

A Review of Antibody Drug Conjugate (ADC) treatments for Lymphoma Read More »